1	
2	
3	
4	The efficacy of Tripterygium Glycosides in the treatment of Chinese patients
5	with thyroid-associated orbitopathy: A systematic review and meta-analysis
6	
7	
8	Mingzhe Li ^a , Bingchen Wei ^{b*} , Tianshu Gao ^c , Chenghan Gao ^c
9	
10	
11	
12	1 Internal Medicine Department, the Third Affiliated Hospital of Liaoning University of Traditional Chinese
13	Medicine, Shenyang, China
14	2 The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, China
15	3 The First Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang, China
16	
17	*Correspondence: Bingchen Wei,

18 E-mail: m18540119119@163.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

Objective: This study aims to conduct a systematic review of the effectiveness and safety of Tripterygium
 Glycosides interventions in the treatment of Chinese patients with thyroid-associated orbitopathy (TAO).

Methods: A literature search was conducted using PubMed for English sources, and the CNKI, Chinese Biomedical Database, Wanfang Database, and VIP Database for Chinese sources. The search period extended from the beginning of the databases' creation to Dec. 2023. The keywords used in the search were hyperthyroidism, thyroid-related immune orbitopathy (TRIO), ophthalmopathy, and Tripterygium Glycosides. Various combinations of search terms were used, depending on the database being queried. All the trials included in the study were clinical randomized controlled trials (RCTs).

29 **Results:** 33 RCTs or quasi-RCTs that met the inclusion criteria were included. The meta-analysis included 27 RCTs. 6 RCTs were excluded from the analysis due to the absence of a control group, but they were still included 30 in the systematic review. 27 RCTs or quasi-RCTs involving 2,134 patients were included in the meta-analysis. 31 32 The TRIO patients in the treatment group received Tripterygium Glycosides in combination with Thiamazole, 33 Prednisone, Levothyroxine sodium, or a combination of these medications. While the TRIO patients in the control group were treated with Thiamazole, Prednisone, Levothyroxine sodium, or a combination of these treatments, the 34 35 meta-analysis results show that the overall effectiveness rate of the treatment group and the control group was P =0.05, $I^2 = 0.33 < 0.5$ [MD = 4.45, 95% CI (3.31, 5.99), P < 0.00001]. The former was significantly superior to the 36 latter. At the same time, a risk assessment was conducted for the study of the 2 groups. The former was 37 significantly superior to the latter. Furthermore, the clinical effectiveness rate of eyeball prominence was P < 0. 38 00001, $I^2 = 0.98 > 0.5$ [MD = 2.40, 95% CI (2.28, 2.51), P < 0.00001]. The clinical effectiveness rate of CAS 39 score was P < 0.00001, $I^2 = 0.89 > 0.5$ [MD = 1.68, 95% CI (1.50, 1.85), P < 0.00001]. The clinical effectiveness 40 rate of FT₃ was P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001], the clinical 41 effectiveness rate of FT₄ was P < 0.00001, $I^2 = 0.95 > 0.5$ [MD = 2.12, 95% CI (1.99, 2.25), P < 0.00001], and 42 43 44 00001].

45 **Conclusion**: The experience with the treatment of TAO using Tripterygium Glycosides was promising. The 46 existing evidence suggests that treatment with Tripterygium Glycosides may be more effective in enhancing the 47 response rate, quality of life, and FT₃ levels compared to treatment with Prednisone, Levothyroxine sodium, 48 and/or Thiamazole alone.

49 *Keywords:* Hyperthyroidism; Thyrotoxicosis; Thyroid-associated orbitopathy; Tripterygium Glycosides; Meta-analysis

50 **1. Introduction**

51 Thyroid-associated ophthalmopathy (TAO) is a group of autoimmune diseases involving orbital and periocular 52 tissues associated with genetic, environmental, and immunologic factors, with the highest incidence of orbital disease. 53 The pathogenesis of the disease is complex, with the majority of patients suffering from Graves' disease (GD), which 54 has a prevalence of up to 40%. Moreover, in 80% of patients experiencing both hyperthyroidism and ophthalmopathy, 55 the clinical symptoms progress rapidly within 2 years of disease onset, forming a vicious cycle [1]. Graves' ophthalmopathy is also known as thyroid eye disease (TED), thyroid-associated orbitopathy (TAO), and Graves' 56 orbitopathy (GO) [2,3]. Tripterygium wilfordii is the Chinese herbalanti-inflammatory immunomodulator, which is the 57 58 first studied andused in China, known as the "Chinese herbal hormone". It has thefunctions of promoting blood 59 circulation and collateralization, dispelling wind and dehumidification, detumescence and pain, detoxification, anti-60 inflammatory and etc. Extract of tripterygium wilfordii is often used in the treatment of autoimmune diseases. There is a 61 large number of clinical studies having found thattriptervgium wilfordii can be used in the treatment of thyroid-62 associated ophthalmopathy [4]. Currently, the use of Tripterygium and its extracts for treating hyperthyroidism 63 exophthalmos is gaining clinical attention. Comprehensive analysis and evaluation of RCTs on TAO with Tripterygium Glycosides were carried out in this paper according to principles of evidence-based medicine. A meta-analysis was 64 65 conducted to provide objective and accurate evidence, and to assess the effectiveness of Triptervgium Glycosides in treating hyperthyroidism exophthalmos. The aim was to offer guidance and a foundation for the clinical use of this 66 67 medication.

Tripterygium wilfordii is a perennial vine species in the Celastraceae family, extensively utilized in traditional Chinese medicine for the treatment of autoimmune and inflammatory diseases. According to the *Compendium of Materia Medica*, Tripterygium wilfordii is documented as a treatment for conditions such as swelling, edema, accumulation, yellow and white pox, long-term incurable malaria, constipation, leprosy, and falls.

The protocol of this network meta-analysis was registered in PROSPERO with ID CRD42021247873. We present the following article in accordance with the PRISMA reporting checklist (available at https://dx.doi.org/10.21037/apm-21-1307).

75 **2. Methods**

76 2.1. Literature sources and search

77

The publications utilized in the meta-analysis were identified through searches of the China National Knowledge

Infrastructure (CNKI), PubMed, Web of Science, Wanfang Database, VIP Database, and EMBASE. The search period 78 79 extended from the inception of the databases' construction to December 2023, and the search was conducted in Chinese 80 or English. The key words used in the search were "Hyperthyroidism", "Thyroid related immune orbitopathy" or 81 "TRIO", "Ophthalmopathy" or "Tripterygium Glycosides", "Tripterygium, Tripterygium wilfordii", "Tripterygium 82 wilfordii Hook f.", "Tripterygium wilfordii multiglycoside". Different combinations of search terms were used, depending on the selected database. The selected publications were clinical trials published in medical journals. 2 83 reviewers independently evaluated English and Chinese literature for inclusion. Any disagreements were resolved 84 85 through discussion.

86 2.1.1. Literature selection

Research on the types of RCTs (RCT or Controlled Clinical Trial, CCT) for the treatment of TAO, regardless of
whether blinded or not.

B9 Diagnose standard according to the *Diagnosis of clinical diseases based on the improvement of the standard* [5]: (1)

typical ocular symptoms; (2) with hyperthyroidism or a history of hyperthyroidism; and (3) excluding other similar
diseases.

Exclusion criteria: (1) myopia; (2) orbital inflammatory pseudotumor; (3) carotid-cavernous sinus fistula or dural
 artery cavernous sinus; (4) extraocular muscle lymphatic tumor; (5) primary orbital tumor; (6) ocular metastasis; and (7)
 intracranial tumors and other diseases.

TAO classification according to Wilmar's simple classification standard. Grade I (mild): eyeball prominence < 18mm, with upper eyelid retraction, gaze, eyelid, and conjunctival edema; Grade II (moderate): eyeball prominence is 18-20 mm, with ocular involvement; Grade III (severe): eyeball prominence > 20 mm, with corneal involvement and vision disorders [6].

99 2.1.2. Literature extraction

Studies were excluded if they were: (1) animal experiments; (2) clinical trials from which no relevant data could be extracted; (3) repeatedly published studies; (4) studies involving patients with serious mental disorders or dementia; (5) studies involving patients with serious systemic symptoms that may significantly affect their ability to perform daily living activities, including syncope or coma, seizure-like headache, and cachexia; and (6) studies involving pregnant or breastfeeding women.

All trials included in the analysis were extracted by two reviewers. Once completed, any disagreements regarding data extraction and study evaluation were resolved through discussion with the third reviewer. All the trials included in the analysis contain information on study design, patient characteristics, and medication use.

108 **2.2. Clinical efficacy**

109 Clinical efficacy judgement [7,8]: Cure is defined as the disappearance of eye symptoms, obvious retraction of the 110 eye, protrusion of the eyeballs < 18 mm, or a reduction in protrusion by > 3 mm. The treatment was significantly 111 effective as the eye symptoms disappeared, but the reduction in exophthalmos > 2 mm. The degree of reduction in 112 exophthalmos is effective, ranging from 1-2 mm. Invalid: The degree of exophthalmos showed no obvious change, or 113 exophthalmos reduced by < 1 mm.

114 **2.3. Quality assessment**

Following the quality assessment standard recommended by the Cochrane Review Handbook 5.0 [^{9]}. The bias risk assessment tool involved six aspects: (1) random distribution method; (2) concealment of allocation decisions; (3) blinding of research subjects, operators of the therapeutic plan, or those measuring the results; (4) result integrity; (5) selective presentation of study findings; and (6) other potential sources of bias.

Each research result was evaluated based on the six aspects mentioned above and categorized as "YES" (lowdegree bias), "NO" (high-degree bias), or "unclear" (lacking relevant information or uncertain bias condition). Two evaluators cross-verified the quality assessment results of the inclusive trials, and any differences in opinions were resolved through discussion or third-party arbitration.

123 **2.4. Statistical analysis**

124 Meta-analysis was performed using the Rev Man software (Version 5.3) from The Cochrane Collaboration website. First, we performed clinical heterogeneity and methodological heterogeneity analyses for all the trials included. 125 126 Statistical heterogeneity was evaluated by the Chi-squared (χ^2) test and heterogeneity were considered present if $P \leq 1$ 0.10. A quantitative assessment of heterogeneity was performed using I^2 where $I^2 > 50\%$ indicated high heterogeneity 127 128 among study results. Study results were pooled for analysis using a fixed effects model when there was no statistical 129 heterogeneity or using a random effects model when statistical heterogeneity was detected. For dichotomous variables, 130 odds ratio (OR) and 95% confidence interval (CI) was determined. For hypothesis testing, the U test was used and the 131 results were presented as Z and P values. The differences in the efficacy between interventions were considered 132 statistically significant if $P \le 0.05$. The results of hypothesis testing are presented in a forest plot.

133 **3. Results**

134 **3.1. Identified studies and characteristics**

The literature search yielded a total of 211 published studies. The abstracts of these studies were reviewed, and subsequently, 142 studies were excluded due to a lack of controls. The 69 potentially relevant RCTs were further reviewed, of which 36 were excluded due to the low Jaded score. Finally, 33 RCTs or quasi-RCTs that met the inclusion criteria were included. 27 RCTs were included in the meta-analysis, while 6 RCTs were excluded due to the absence of a control group, but they were included in the systematic review (Fig 1). A total of 33 RCTs with a diagnosis of TAO were included (Table 1).

141 Fig 1 Flow diagram for identification of eligible literatures for this meta-analysis.

142 **Table 1** The main characteristics of the trials.

First outbor	Gender (Mala/	Range of age	Tme	Intervention	Main outcomes	
FIrst author	(Male/ Female)	age (years)	(weeks)	Treatment group	Control group	Wiam outcomes
Nie M[10]	92 (51/41)	31-56 (43.81±5.12)	36	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Eyeball prominence, TSH, FT ₄ , Clinical effect
Tian ML[11]	44 (17/27)	20-62 (40.98±10.45)	24	⁹⁹ Tc-MDP, Glycosides tablets	Glycosides tablets	Eyeball prominence, FT ₃ , FT ₄ , Clinical effect
Chang XY[12]	86 (51/35)	29-58 (44.37±10.67)	12	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Clinical effect
Xue F[13]	100 (-/-)	- (-)	12	Thiamazole, Levothyroxine Sodium, Prednisone, Glycosides tablets	Thiamazole, Levothyroxine Sodium, Prednisone	Eyeball prominence, Clinical effect
Gao X[14]	90 (55/35)	30-50 (40.91±10.11)	Blank	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Clinical effect, Quality of life score
Chi PW[15]	108 (55/53)	21-49 (33.9±5.3)	12	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Eyeball prominence, Clinical effect
Li XL[16]	80 (35/45)	20-46 (32.2±3.5)	12	Levothyroxine Sodium, Thiamazole, Prednisone, Glycosides tablets Glycosides tablets Levothyroxine Sodium	Levothyroxine Sodium, Thiamazole, Prednisone	Eyeball prominence, Clinical effect
Yue X[17]	53 (20/33)	- (40.2±14.1)	Blank	Methylprednisolone, Hydrochlorothiazide, Potassium chloride sustained-release tablets	Blank	Clinical effect, CAS score
Ma CF[18]	80 (34/46)	20-49 (33.2±1.2)	12	Thiamazole, Glycosides tablets	Thiamazole	Eyeball prominence, Clinical effect
Ao W[19]	80 (31/49)	21-45 33.2±2.4	12	Levothyroxine Sodium, Thiamazole, Prednisone, Glycosides tablets	Levothyroxine Sodium, Thiamazole, Prednisone	Eyeball prominence, Clinical effect
Li XH[20]	114 (41/73)	20-55 (35.70±8.20)	12	Levothyroxine Sodium, Thiamazole,, Prednisone, Glycosides tablets	Levothyroxine Sodium, Thiamazole, Prednisone	Eyeball prominence, Clinical effect
Luo J[21]	50 (16/43)	- (46.23±12.17)	16	Methylprednisolone, Prednisone, Glycosides tablets	Methylprednisolone, Prednisone	Clinical effect, CAS Score
Xv JP[22]	64 (29/55)	- (33.0±11.5)	12	Levothyroxine Sodium, Thiamazole, Prednisone, VitD, Glycosides tablets	Levothyroxine Sodium, Thiamazole, Prednisone, VitD	Eyeball prominence, Clinical effect, Peripheral blood cytokine levels
Zhang JF[23]	49 (19/30)	22-47 (28.3±6.9)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Thiamazole, Prednisone, Levothyroxine sodium	Eyeball prominence, Clinical effect
Jiang WH[24]	84 (21/63)	(38.45±1.75)	12	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Clinical effect, CAS Score
Cui HH[25]	75 (-/-)	12-70 (40.9±13.1 & 37.9±14.5)	12	Prednisone, Glycosides tablets	Prednisone	Clinical effect, CAS score
Liao XD[26]	66 (27/39)	18-50 (32.6±2.9)	12	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Clinical effect
Lin YL[27]	122 (41/81)	18-66 (39.25)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Blank	Clinical effect
Wu JT[28]	60 (22/38)	19-58 (-)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Blank	Clinical effect
Gou XY[29]	48 (12/36)	16-70 (43.20±10.15)	12	Cetirizine tablets, Glycosides tablets	Prednisone	Clinical effect, CAS score
Zhang ZY[2]	98 (38/60)	19-49 (33.50)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Thiamazole, Prednisone, Levothyroxine sodium	Clinical effect
He XH[30]	39 (13/26)	16-65 (47.24±11.16)	16	Glycosides tablets, Prednisone, ATD	Prednisone, ATD	Clinical effect, Eyeball prominence, T-cells
Zheng ST[31]	40 (9/31)	19-48 (35±5.5)	12	ATD, Nimesulide, Glycosides tablets, ⁹⁹ Tc- MDP	ATD	Clinical effect, FT ₃ , FT ₄ , TSH, TGAb, TPO-Ab
Wei XB[32]	84 (35/49)	20-56 (35.4)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Thiamazole, Prednisone, Levothyroxine sodium	Eyeball prominence, Clinical effect
Wang XS[33]	106 (44/62)	(38.80)	16	Glycosides tablets, 99Tc-MDP	Prednisone	Eyeball prominence, CAS Score, Clinical effect
Mu YD[34]	61 (23/38)	17-64 (37.48)	12	Thiamazole, Prednisone, Glycosides tablets	Blank	Clinical effect
Xie DH[35]	60 (17/43)	17-49 (36.00±5.50)	12	ATD, 99Tc-MDP, Thiamazole	ATD	Clinical effect, FT ₃ , FT ₄ , TSH, TGAb, TPO-Ab
Zuo LJ[36]	215 (89/126)	(48.07)	12	ATD, ⁹⁹ Tc-MDP, Thiamazole, Glycosides tablets	ATD	Clinical effect, FT ₃ , FT ₄ , TSH, TGAb, TPO-Ab
Wang L[37]	49 (19/30)	20-53 (-)	12	Thiamazole, Glycosides tablets	Thiamazole	CAS Score

Wang W[38]	48 (21/27)	30-63 (44)	16	¹³¹ I, Glycosides tablets	¹³¹ I, Prednisone	Clinical effect, CAS Score
Lv JZ[39]	22 (9/13)	20-52 (31)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Blank	FT ₃ , FT ₄ , TSH, TGAb, TPO-Ab
Luo Y[40]	86 (56/30)	17-52 (34±1.52)	8	Glycosides tablets	VitB ₁ , VitC	Eyeball prominence
Wang XM[41]	36 (14/22)	(-)	8-52	Glycosides tablets	Blank	FT ₃ , FT ₄ , TGAb, CIC

143 Notes: FT₃: free triiodothyronine; FT₄: free thyroxine; TGAb: thyroglobulin antibody; CIC: cycle immune complex;

144 TSH: thyroid stimulating hormone; ATD: Antithyroid Drug; CAS Score: clinical activity score.

145 **3.2. Quality assessment**

According to the quality evaluation standard for all included RCTs and CCTs for quality assessment and analysis.

147 11 RCT articles were rated as B grade. 16 articles received a C grade. The evaluation and results are presented in Table

148 1 and 2. Trials of poor quality (D grade) were excluded.

Table 2. The methodological quality of the trials.

First author	Year	City, Provice, Country	Random	Blind method	Baseline consistency	Fall off	Follow up	Adverse eventss	Grade
Nie M[10]	2021	Changyuan, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	В
Tian ML[11]	2020	Puyang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Chang XY[12]	2019	Tieling, Liaoning, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Xue F[13]	2019	Weifang, Shandong, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Gao X[14]	2018	Lingyuan, Liaoning, China	Unclear	Unclear	Consensus	Unclear	Unclear	Unclear	С
Chi PW[15]	2017	Xuchang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	В
Li XL[16]	2017	Yulin, Shaanxi, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Yue X[17]	2017	Zhengzhou, Henan, China	Unclear	None	Consensus	Unclear	Unclear	Mentioned	В
Ma CF[18]	2016	Bayannur, Inner Mongolia, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Ao W[19]	2015	Zhengzhou, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Li XH[20]	2015	Anyang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Luo $J[21]$	2015	Enshi, Hubei, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	В
Xv JP[22]	2014	Jinhua, Zhejiang, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	В
Zhang JF[23]	2014	Shaoxing, Zhejiang, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	В
Jiang WH[24]	2013	Huangshi, Hubei, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Cui HH[25]	2013	Nanjing, Jiangsu, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	В
Liao XD[26]	2012	Leshan, Sichuan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	В
Lin YL ^[27]	2012	Nanning, Guangxi, China	Unclear	None	Consensus	Unclear	Unclear	Unclear	С
Wu JT[28]	2012	Jiyuan, Henan, China	Unclear	None	Consensus	Unclear	Unclear	Mentioned	В
Gou XY[29]	2012	Chongqing, China	Mentioned	Unclear	Consensus	Unclear	Unclear	None	В
Zhang ZY[2]	2010	Pingdingshan, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	В
He XH[30]	2010	Guiyang, Guizhou, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	В
Zheng ST[31]	2010	Siping, Jilin, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	С
Wei XB[32]	2009	Luoyang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	В
Wang XS[33]	2009	Hengshui, Hebei, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	С
Mu YD[34]	2009	Shangqiu, Henan, China	Unclear	None	Consensus	Unclear	Unclear	Unclear	С
Xie DH[35]	2007	Zhuhai, Guangdong, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	В
Zuo LJ[36]	2007	Kunming, Yunnan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	None	С
Wang L[37]	2007	Yurao, Zhejiang, China	Unclear	Unclear	Consensus	1 case	Unclear	Mentioned	В
Wang W[38]	2004	Xinxiang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Mentioned	Unclear	В
Lv JZ[39]	2003	Ningbo, Zhejiang, China	Unclear	None	Consensus	Unclear	Unclear	Mentioned	В
Luo Y[40]	2002	Taiyuan, Shanxi, China	Unclear	None	Consensus	Unclear	Unclear	Unclear	С
Wang XM[41]	1995	Yangzhou, Jiangsu, China	Unclear	None	Consensus	Unclear	Unclear	Unclear	С

151 **3.3. Results of meta-analysis**

152 33 RCTs or CCTs were published between 2002 and 2021 in China. There were 2,134 cases in 27 RCTs, with 1,104 cases in the treatment group and 1,030 cases in the control group. The treatment group received Tripterygium 154 Glycosides in combination with Thiamazole, Prednisone, Levothyroxine sodium, or a combination of these medications. 155 While the TRIO patients in the control group were treated with Thiamazole, Prednisone, Levothyroxine sodium, or a 156 combination of these treatments. The treatment effect was categorized into four grades: cured, significantly effective, 157 effective, and invalid.

158 Heterogeneity among studies was assessed using Cochran's Q test. The P value (P < 0.01, $I^2 < 0.5$) of the Q test <

159 0.01, a random effect model was used; otherwise, a fixed effect model was used. For each model, the effect summary

160 odds ratio (OR) and its 95% CI were calculated.

Meta-analysis results showed that the overall effectiveness rate of TAO treatment in the treatment group and the control group was P = 0.05, $I^2 = 0.33 < 0.5$ [MD = 4.45, 95% CI (3.31, 5.99), P < 0.00001], with the former significantly outperforming the latter. At the same time, a risk assessment was conducted for both groups in the study (Fig 2).

165 Fig 2 The clinical effectiveness rate.

166 The clinical effectiveness rate of eyeball prominence was P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 2.40, 95% CI (2.28,

- 167 2.51), *P* < 0. 00001] (Fig 3).
- 168 Fig 3 The clinical effectiveness of the eyeball prominence.

169 The clinical effectiveness rate of CAS score was P < 0.00001, $I^2 = 0.89 > 0.5$ [MD = 1.68, 95% CI (1.50, 1.85), P

- 170 < 0. 00001] (Fig 4).
- 171 Fig 4 The clinical effectiveness of the eye CAS score.

The clinical effectiveness rate of FT₃ was P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), P < 0.00001]

173 00001] (Fig 5A), the clinical effectiveness rate of FT_4 was P < 0.00001, $I^2 = 0.95 > 0.5$ [MD = 2.12, 95% CI (1.99,

174 2.25), P < 0.00001 (Fig 5B), and the clinical effectiveness rate of TSH was P < 0.00001, $I^2 = 0.89 > 0.5$ [MD = -0.19,

175 95% CI (-0.21, -0.17), *P* < 0. 00001] (Fig 5C).

176 Fig 5 The clinical effectiveness rate of the FT₃, FT₄, and TSH.

177 **3.4. Adverse events**

178 11 studies reported adverse events. In Chi PW's study [15], 7 instances of nausea and vomiting, 3 instances of 179 reduced appetite, and 2 instances of diarrhea were reported in the control group. In the observation group, 2 cases of 180 nausea and vomiting, 1 case of reduced appetite, and 1 case of diarrhea were reported. In Yue X's study [17], adverse

181 reactions mainly occur during hormone shock and the application of somatostatin. Among them, there were 21 cases of 182 abdominal distension, 5 cases of diarrhea, 11 cases of nausea, 5 cases of vomiting, and 3 cases of hypoglycemia, mainly 183 during the use of somatostatin. Additionally, there were 13 cases of abnormal blood glucose: 10 cases of elevated 184 fasting blood glucose levels and 3 cases of early morning hypoglycemia. The elevated fasting blood glucose mainly 185 occurred during the hormone shock treatment period. After 1 week, the fasting blood glucose levels were within the 186 normal range upon re-examination. Exciting insomnia mainly occurs during the hormone pulse therapy period, and the symptoms disappear after the completion of the pulse therapy. There were 4 cases of transient elevated blood pressure, 187 188 4 cases of abnormal liver function, and 1 case of hypokalemia. In Luo J's study [21], 8 cases in the observation group 189 experienced weight gain, elevated blood sugar, elevated blood pressure, and upper abdominal discomfort, respectively. 190 In the control group, 15 cases experienced weight gain, hirsutism, epigastric discomfort, elevated blood glucose, 191 elevated blood pressure, and elevated liver transaminase. In Xv JP's study [22], the control group had 3 cases of weight 192 gain, 1 case of osteoporosis, and 3 cases of peptic ulcers. In the treatment group, there were 3 cases of mild increases in 193 serum alanine aminotransferase and 3 cases of decreased menstrual flow. In Cui HH's study [25], 2 cases experienced 194 mild menstrual abnormalities, 2 cases experienced stomach discomfort, 1 case had mild transaminase abnormalities, 1 195 case gained weight during medication, and exhibited Cushing's face in the control group. After 1 month of medication, 196 limb muscle stiffness occurred, but no significant changes in blood glucose were observed in all patients. There were 4 197 cases of mild menstrual abnormalities and 1 case of erythra in treatment group II. In Wu JT's study [28], 4 cases 198 showed a decrease in WBC, 2 cases experienced gastrointestinal reactions, and 1 case had mild liver dysfunction. All of 199 them recovered after receiving symptomatic treatment. In He XH's study [30], 3 cases experienced weight gain and 200 hirsutism, while 2 cases experienced acid reflux and upper abdominal discomfort in the treatment group. In Wang XS's 201 study [33], there were 4 cases of short-term blood glucose elevation and 7 cases of insomnia due to excitement in the 202 control group during the treatment process. The aforementioned side effects gradually disappeared with the decrease in hormone dosage, and no special treatment is needed. In Xie DH's study [35], a small number of patients experienced 203 204 vascular pain at the ⁹⁹Tc MDP infusion site. The discomfort symptoms disappeared after the infusion speed was reduced 205 in the treatment group. Some patients experienced weight gain and excessive nighttime urination after receiving low doses of dexamethasone, and no abnormalities were found in routine blood and urine tests. After the treatment, and 206 207 routine blood and urine tests did not reveal any abnormalities. In Wang L's study [37], 1 woman experienced 208 amenorrhea and withdrew from the observation. However, she recovered after discontinuing the medication. In Lv JZ's 209 study [39], 21 cases experienced anorexia, nausea, vomiting, and diarrhea, and their symptoms were relieved.

210 **3.5. Risk of bias within studies**

211

Publication bias analysis was conducted on these 27 pieces of literature using a funnel plot, which resulted in a

symmetric distribution. Begg's test and Egger's test were also conducted. Both of the *P* values were > 0.05, indicating that there was no publication bias in the included trials. All the matching points were found within the 95% CI.

214 The bias was evaluated by conducting a funnel plot analysis of the Tripterygium Glycosides treatment for TAO. 215 The accuracy improved as the sample size increased. The amount of literature included is insufficient, scattered within 216 the pyramid, and symmetrically distributed alongside the axis, indicating minimal bias (Fig 6A). The points corresponding to the CAS score (Fig 6C), FT₄ (Fig 6E), and TSH (Fig 6F) in the included trials are primarily situated 217 within the 95% CI, with a scattered distribution within the range, basically symmetrical on both sides, and presenting a 218 219 funnel-shaped shape, indicating a small publication bias in the trials included. The eyeball prominence (Fig 6B) 220 corresponding points were outside the range of the 95% CI. This may be attributed to factors such as small sample 221 studies, non-significant results not being published or cited. The corresponding point of FT_3 (Fig 6D) is asymmetric on 222 both sides of the axis.

223 Fig 6 Funnel plot of the literatures analyzed in the meta-analysis.

4. Discussion

225 TAO is a multifactorial ocular disorder caused by thyroid disease, which often manifests as eye redness, eye pain, 226 exophthalmos, edema, and impaired movement of periocular muscles, etc. 40%-70% of TAO patients suffer from 227 hyperthyroidism. Currently, TAO is clinically categorized into two types: one is ocular infiltrative type, also known as endocrine ophthalmoplegia or malignant Graves' ophthalmopathy, which accounts for 5%-10% of patients with 228 229 hyperthyroidism. The other is the non-infiltrative type of ophthalmoplegia, also known as simple or benign 230 exophthalmoplegia, which is usually caused by sympathetic stimulation of the periorbital or upper facial muscles. 231 Ocular infiltrative TAO is an autoimmune disease caused by hyperplasia, lymphocytic infiltration and edema of the 232 retro-ocular tissues and is influenced by a variety of factors, such as smoking, genetics and the environment [18,44].

The early pathologic changes in these diseases are the infiltration of lymphocytes and serum cells into the periocular muscles and connective tissues [45-47].

During the course of the disease, there is a buildup of collagen in the periocular muscles, which leads to fibroblasts and fat cell deposits, the presence of which is of greater significance because it indirectly confirms that the disease undergoes a longer and slower progression. The presence of fat deposits is more significant because it indirectly confirms that the disease undergoes a longer and slower progression. Current research suggests that the correlation between thyroid disease and ocular symptoms may explain the following findings: (1) edema leading to an increase in the volume of the contents of the eye sockets; (2) the production of hydrophilic glucosamines and peptidoglycans; and (3) an accumulation of adipose tissue in the eye sockets.

At the present time, the combined use of tretinoin preparations for the treatment of infiltrative TAO is widely used

in the clinic. This study found that treatment with Tripterygium Glycosides may be more effective in enhancing the response rate, quality of life, and FT₃ levels compared to treatment with Prednisone, Levothyroxine sodium, and/or Thiamazole alone. Although adverse reactions were still present in the control group, overall the rate of adverse events was lower in the observation group and the clinical benefit was much higher than in the control group. At the same time, a large body of medical evidence shows that Tripterygium Glycosides is effective in the treatment of eye protrusion in hyperthyroidism. It can inhibit cellular and humoral immunity and improve the immune status of the body. It has also been shown to inhibit the formation of self-antigens in the tissues behind the eye, thereby reducing eye protrusion [48].

250 Tripterygium Glycosides is a traditional herbal medicine that originated from China. It has been widely used in 251 China for the treatment of various diseases, including rheumatic diseases, skin diseases, and diabetic nephropathy. In 252 recent years, there have been international studies conducted on Tripterygium Glycosides by renowned institutions such 253 as Harvard University and the University of California, Los Angeles (U.S.A.), the Institute of Pharmacology and Osaka 254 University (Japan), the Siberian Branch of the Russian Academy of Sciences and the Russian Federal Institute of 255 Medical and Biotechnological Research (Russia), as well as the Indian Academy of Medical Sciences and the University of Delhi (India). The research conducted in these countries has mainly focused on studying the 256 257 pharmacological effects, clinical applications, quality control, and other aspects of Triptervgium Glycosides.

Through systematic analysis, we found that the clinical results of applying Tripterygium Glycosides were significantly better than those of the control group. This fully explains the safety, reliability, and precise clinical efficacy of the use of Tripterygium Glycosides in the treatment of hyperthyroid eye protrusion. In addition, Tripterygium Glycosides may improve the efficacy of the basic treatment and may lead to a reduction of the drug dose or complete discontinuation of the treatment. Based on these characteristics, Tripterygium Glycosides treatment may be an ideal solution for hyperthyroidism-like herniated eye disease.

It is important to note that long-term use of Tripterygium Glycosides can cause some damage to various body 264 systems. For example, long-term use of Tripterygium Glycosides at higher-than-average doses can lead to reversible 265 266 liver and kidney damage, while approximately 20% of patients experience gastrointestinal reactions such as loss of 267 appetite, nausea, vomiting, abdominal pain, diarrhea, or constipation. As for the hematopoietic system, the effects of Triptervgium Glycosides use are mainly manifested in the form of a decrease in the number of white blood cells and 268 269 platelets included [49,50]. It has even been found that long-term use of Tripterygium Glycosides causes skin and 270 mucosal reactions such as oral mucosal ulcers, dryness of the mouth and eyes, roughness and dryness of the skin, rashes, 271 skin sclerosis, and increased melanin production, which is usually associated with the inhibition of the IL-23/IL-17 272 pathway [51,52]. In addition, long-term use of Triptervgium Glycosides can inhibit ovarian function and cause 273 menstrual disorders such as decreased menstrual flow or amenorrhea in women, and in men, it may lead to a decrease in

sperm count or sperm motility [53,54].

Despite the inevitable problems associated with the use of Tripterygium Glycosides in the treatment of disease, its benefits in the treatment of various diseases cannot be ignored. Currently, there are several meta-analyses of interest due to the efficacy of Tripterygium Glycosides in the treatment of renal diseases, dermatological disorders, rheumatoid arthritis, and nephrotic syndrome ⁵⁵⁻⁵⁸. Therefore, it is crucial to conduct a multicenter randomized, double-blind clinical trial to study the efficacy of trehalose in TAO [59,60].

280 **5. Conclusion**

This meta-analysis demonstrates that the experience with the treatment of TAO using Tripterygium Glycosides was promising. The existing evidence suggests that treatment with Tripterygium Glycosides may be more effective in enhancing the response rate, quality of life, and FT_3 levels compared to treatment with Prednisone, Levothyroxine sodium, and/or Thiamazole alone.

Declaration of Competing Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. We declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. The manuscript has been read and approved by all the mentioned authors.

290 **References**

- 1.Ying JM. Progress of Chinese medicine in treating hyperthyroid exophthalmos. *Journal of Traditional Chinese Medicine*.25:979-981(2009).
- 2.Zhang ZY, Wang JH. Tripterygium Glycosides with tapazole and prednisone in the treatment of hyperthyroidism
 exophthalmos. *Journal of Medical Forum*. 31 (8): 110-111(2010).
- 295 3.Webb MS, John stone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, et al. In vitro and in vivo characterization
- of a combination chemotherapy formulation consisting of vinorelbine and phosphatidyl bine. *European Journal of*
- 297 *Pharmaceutics and Bio pharmaceutics*. 65 (165): 289-299(2010).
- 4.Li XW. Clinical observation of 50 cases of children with purpura nephritis treated with Tripterygium Glycosides
 tablets. *Jiangsu Medical Journal*. 12: 664-665(1987).
- 300 5.Ministry of health of the people's Liberation Army General Logistics Department. Diagnosis of clinical diseases
- 301 based on the improvement of the standard. *Beijing: People's military medical press*. 1198-1991(1987).

- 302 6.Ministry of Health, PRC. Guiding principle of clinical research on new drugs of Traditional Chinese Medicine.
- 303 Beijing: The Medicine Science and Technology Press of China. section 1: 168(1993).
- 304 7.Wiersinga WM, Prummel MF. Grave's ophthalmopathy: a rational approach to treatment. *Trends Endocrinal* 305 *Metabolism.* 13 (7): 280(2002).
- 306 8.Gu MJ, Wu WY, Liu CH, Liu XL, Li X, Liu ZM. Efficacy of prednisone in the treatment of thyroid associated
- 307 ophthalmopathy on adrenocortical function. *Journal of Xi'an Jiaotong University: Medical Sciences*. 24 (2): 177 308 178(2003).
- 9.Higgins JPT, Green S.Cochrane Handbook for Systematic Reviews of Interventions Version 5.3 [updated March,
 2015].*The Cochrane Collaboration*,(2015).
- 311 10.Nie M. Efficacy evaluation of Tripterygium wilfordii polyglycoside combined with Thiamazole and prednisone
- acetate tablets in the treatment of hyperthyroid exophthalmos. *Heilongjiang Journal of Traditional Chinese Medicine*. 50(3):162-163(2021).
- 11Tian ML. Therapeutic effect of Tripterygium wilfordii polyglycoside combined with technetium 99 methylenediphosphonate on thyroid associated ophthalmopathy. *Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine*. 20(5):17-18(2020).
- 12.Chang XY. Effect of Tripterygium wilfordii polyglycoside combined with tapazole and prednisone on
 hyperthyroidism exophthalmos. *Guide of China Medicine*, 17(21):167-168.
 DOI:10.15912/j.cnki.gocm.(2019).21.129(2019).
- 13.Xue F, Zhang WJ. Analysis of the symptom and outcome of hyperthyroidism exophthalmos treated with
 Tripterygium wilfordii glycosides. *World Latest Medicine Information*. 19(46):214. DOI:10.19613/j.cnki.1671 3141.2019.46.127(2019).
- 14.Gao X. Evaluation of the clinical efficacy of Tripterygium wilfordii polyglycoside, tapazole and prednisone in the
 treatment of hyperthyroid exophthalmos. *Guide of China Medicine*. 16(2):187-188.
 DOI:10.15912/j.cnki.gocm.2018.02.157(2018).
- 15.Chi PW. Clinical analysis of Tripterygium wilfordii polyglycoside combined with Thiamazole and prednisone in the
 treatment of hyperthyroid exophthalmos. *Journal of North Pharmacy*. 14(9):34-35(2017).
- 16.Li XL, Ma T. Clinical effect of tripterygium glycosides combined with tazobactam and prednisone on patients with
 hyperthyroid exophthalmos. *Clinical Research and Practice*. 2(22):75-76. DOI:10.19347/j.cnki.2096 1413.201722037(2017).

- 331 17.Yue X, Wang YY, Yang Y, Wen SM, Sun LG. Clinical efficacy and safety analysis of glucocorticoids combined
- with somatostatin and Tripterygium wilfordii glycosides in the treatment of thyroid associated ophthalmopathy.
 Henan Medical Research. 26(1): 31-33(2017).
- 18.Ma CF, Wang YS. Clinical efficacy of Tripterygium wilfordii glycosides combined with Methimazole in the
 treatment of hyperthyroid exophthalmos. *World Latest Medicine Information*. 16(75):104(2016).
- 336 19.Ao W. Observation on the therapeutic effect of combination therapy of Tabazole, prednisone, and Tripterygium
- wilfordii glycosides in patients with hyperthyroidism exophthalmos. *Medical Journal of Chinese People's Health*.
 27(13):95-96(2015).
- 20.Li XH. Clinical analysis of Tripterygium wilfordii glycosides combined with Tabazolidinolone in the treatment of
 hyperthyroidism exophthalmos. *Clinical Research*. 23(5): 60-61(2015).
- 341 21.Luo J, Huang J, Ye M. The observation of curative effect of glucocorticoids combined with Glucosida Tripterygii
- TOTA in the treatment of Graves' ophthalmopathy. *Practical Journal of Clinical Medicine*. 12(5): 174-176(2015).
- 22.Xv JP, Xv C, Chen J, Jin ZH, Zheng HF, Zhu J. Graves The level of cytokines in peripheral blood of
 ophthalmopathy and the effect of Tripterygium wilfordii polyglycoside intervention. *China Journal of Chinese Materia Medica*. 39(3): 544-547(2014).
- 23.Zhang JF, Kong YZ, Pan HZ. Clinical efficacy of the treatment of hyperthyroidism exophthalmos with Tripterygium
 Glycosides tablets. *Chinese Rural Health Service Administration*. 6: 761-762(2014).
- 24.Jiang WH. Clinical observation of Tripterygium wilfordii polyglycoside combined with tapazole and prednisone in
 the treatment of hyperthyroidism exophthalmos. *World Health Digest*. 10(22): 178-179(2013).
- 350 25.Cui HH, Ye XZ, Li YL, Lu B, Peng L, Xv YX, et al. Clinical efficacy of mycophenolate mofetil and other
- Immunosuppressive drug in the treatment of thyroid associated ophthalmopathy. *Chinese Journal of Clinicians (Electronic Edition)*. 7(24):11197-11200(2013).
- 26.Liao XD. Clinical observation of hyperthyroidism exophthalmos treated with Tripterygium Glycosides combined
 with methimazole and prednisone. *China Health Care and Nutrition*. 10: 1514-1515(2012).
- 27.Lin YL. Treatment 122 cases of hyperthyroidism exophthalmos treated with Tripterygium Glycosides tablets
 combined with methimazole and prednisone. *China Journal of Pharmaceutical Economics*. 7 (5): 119-120(2012).
- 28.Wu JT. Clinical analysis of hyperthyroidism exophthalmos treated with Tripterygium Glycosides tablets combined
 with methimazole and prednisone. *Contemporary Medicine*. 18 (22): 79-80(2012).
- 359 29.Gou XY, Cheng G. Clinical Study on Certirizine Combined Tripterygium Glycosides for Treating 24 Cases of
- 360 Thyroid Associated Ophthalmopathy. *China Pharmaceuticals*. 21(18):85-86(2012).

- 361 30.He XH, Kong DM. Tripterygium wilfordii polyglycosides combined with low-dose prednisone in the treatment of 23
- 362 cases of Graves' ophthalmopathy. *New Chinese Medicine*. 42(8): 65-66(2010).
- 363 31.Zheng ST, Zhang B, Mei F. Multiple enhanced immunosuppression for hyperthyroid exophthalmos: Yunke,
- Nimesulide, Tripterygium wilfordii polyglycoside tablets for Graver ophthalmopathy. *World Health Digest.* 7(23):
 65-66(2010).
- 366 32.Wei XB. The effect of Tripterygium Glycosides tablets on the treatment of hyperthyroidism exophthalmos. *China* 367 *Modern Doctor*. 20: 97+101(2009).
- 368 33.Wang XS, Li GL, Wang Q, Ge CJ, Zhang L. Clinical study of Yunke combined with Tripterygium wilfordii
- 369 glycosides in the treatment of thyroid associated ophthalmopathy. *Chinese Journal of Practical Ophthalmology*.
 370 27(12):1369-1371(2009).
- 34.Mu YD. Case analysis of Tripterygium wilfordii united tapazole prednisone in the treatment of 61 cases of
 thyrotoxic exophthalmoses. *China Medical Herald*. 6 (23): 25-27(2009).
- 373 35.Xie DH, Sun L, Shu XC, Ye LH, Shen J, Lu HY. Combination of technetium [99Tc] methylenediphosphonate,
- dexamasone and tripterygium glucosides in treatment of Graves ophthalmopathy. *Chinese Journal of New Drugs and Clinical Remedies*. 26(12): 905-908(2007).
- 36.Zuo LJ, Yang JS. Observation on the therapeutic effect of ¹³¹I combined with Tripterygium wilfordii glycosides on
 Graves' ophthalmopathy. *China Health Care*. 15(19): 51-52(2007).
- 378 37.Wang L. Immunosuppressive drug therapy for Graves ophthalmopathy. *Zhejiang Clinical Medicine Journal*.
 379 9:197(2007).
- 38. Wang W, Yang B, Sun HJ, Zhou YL. Clinical study of ¹³¹I and glucoside tripterygium total tablets on
 Graves'ophthalmopathy. *Chinese Journal of Nuclear Medicine*. 24(03): 38-39(2004).
- 39.Lv JZ. Prednisone and Tripterygium Glycosides tablets in the treatment of hyperthyroidism exophthalmos. *Zhejiang Journal of Integrated Traditional Chinese and Western Medicine*. 13 (5): 299-230(2003).
- 40.Luo Y, Zheng DW, Wang X, He YQ, Li DP. Clinical Observation of Tripterygium wilfordii Polysaccharide Tablets
 in the Treatment of Thyroid related Orbital Lesions. *China Journal of Chinese Ophthalmology*. 12(2):95-97(2002).
- 386 41.Wang XM.Clinical study on the treatment of hyperthyroidism exophthalmos with Glycosides tablets. Journal of
- 387 Jiangsu TCM. 16 (10): 41-42(1995).
- 42.Shen ZY. The summary and analysis of the influence of Traditional Chinese Medicine on immune function. *Chinese Journal of Integrated Traditional and Western Medicine*. 12:443-6(1992).
- 390 43.Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, Natural History, Risk Factors, and Prevention
- 391 of Graves' Orbitopathy. Front Endocrinol (Lausanne).11:615993. doi: 10.3389/fendo.2020.615993(2020).

- 392 44.Bai Y. Thyroid disease-basic and clinical. *Beijing: Science and Technology Literature Press.* 466-476(2002).
- 45.Shi FX. Observation on the effect of treating Graves eye disease with Tripterygium Glycosides tablets. *New Chinese Medicine*. 21:472-473(1990).
- 46.Yang JH, Duan JG. The progress of hyperthyroidism exophthalmos with the treatment of Chinese medicine
 treatment. *New Journal of Traditional Chinese Medicine*. 35:74(2003).
- 397 47.Li GM, Li GM, Chen LD. A comparative observation on hyperthyroidism exophthalmos with clinical combination
- of Traditional Chinese and Western Medicine. *Chinese Journal of Information on Traditional Chinese Medicine*.
 15:62(2008).
- 400 48.Zheng JR, Lv Y. Clinical and experimental studies of Tripterygium. *Journal of Traditional Chinese Medicine*.
 401 23:74-78(1982).
- 402 49.Liu F. Pharmacological research and clinical application of Tripterygium Glycosides tablets. *Chinese Traditional* 403 *Patent Medicine*. 24:385(2002).
- 50.Li LX, Jin RM, Li Yikui, Fu SG, Huang J, Zhu ZL, et al. Study on the immunosuppressive effect and safety range of
 multiple dosing of Tripterygium Glycosides tablets. *Chinese Journal of New Drugs and Clinical Remedies*.
- 406 25:248(2006).
- 51.Chu WL, Kang ZF, Chan SL, Li WY, Liu J. Research progress on inhibition of ocular neovascularization by Chinese
 herbal monomers. *Journal of Traditional Chinese Ophthalmology*. 29:166-169(2019).
- 409 52.Qin TY, Gao SS, Wang WZ. The inhibitory effect of Tripterygium wilfordii red pigment on the secretion of IL-17
- 410 by peripheral blood mononuclear cells in patients with sympathetic ophthalmitis. *Chinese Journal of Ocular Fundus*411 *Diseases*. 34:51-54(2018).
- 412 53 Li M, Li Y, Xiang L. Efficacy and safety of Tripterygium glycosides as an add-on treatment in adults with chronic
- 413 urticaria: a systematic review and meta-analysis. *Pharm Biol.* 61:324-336. doi:
 414 10.1080/13880209.2023.2169468(2023).
- 415 54 Xie D, Li K, Ma T, Jiang H, Wang F, Huang M, et al. Therapeutic Effect and Safety of Tripterygium Glycosides
- 416 Combined With Western Medicine on Type 2 Diabetic Kidney Disease: A Meta-Analysis. *Clin Ther*. 44:246417 256.e10. doi: 10.1016/j.clinthera(2022).
- 418 55.Li WW, Liu XL, Wu H, et al. Efficacy and Safety of Tripterygium wilfordii Hook.F for IgA Nephropathy: A Meta419 analysis. *Chin J Evid-based Med.* 15:206-214(2015).
- 420 56.Zhang XM, Xiang SM. Analysis of randomized clinical trials of oral GTT tablets in the treatment of psoriasis
- 421 vulgaris. *Guide of China Medicine*. 27:392-393(2013).

- 422 57.Wang JQ, Li GC, Zhou XP, Ma Z. Tripterygium wilfordii extraction for treating rheumatoid arthritis: a meta-
- 423 analysis. Modern Journal of Integrated Traditional Chinese and Western Medicine. 23:1032-1036(2014).
- 424 58.Huang Q, Zeng QM, Zheng YH, Xiong JL. Meta Analysis of Tripterygium wilfordii Combined Glucocorticoid
- therapy in NS Patients. *Journal of Liaoning University of TCM*. 17:145-149(2015).
- 426 59.Sun ZQ. Medical statistics. *Beijing: People's Health Publishing House*. 623(2002).
- 427 60.Wang JY. Evidence based medicine and clinical practice. *Beijing: Science press*. 118-121(2002).

428 Fundings

- 429 Foundation of Liaoning Province Education Administration(L202073). Foundation of Liaoning Province
- 430 Education Administration (L201723). Liaoning Province Famous Traditional Chinese Medicine Studio Construction
- 431 Project.

432 Author contributions

- 433 Conceptualization: Mingzhe Li, Tianshu Gao.
- 434 Data curation: Mingzhe Li, Bingchen Wei.
- 435 Formal analysis: Bingchen Wei, Chenghan Gao.
- 436 Funding acquisition: Mingzhe Li, Tianshu Gao.
- 437 Investigation: Mingzhe Li, Bingchen Wei, Chenghan Gao.
- 438 Methodology: Mingzhe Li, Tianshu Gao.
- 439 Writing-original draft: Mingzhe Li, Bingchen Wei.
- 440 Writing-review: Mingzhe Li, Bingchen Wei, Chenghan Gao, Tianshu Gao.

Α

	Treatment group			Cont	rol gro	oup		Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI Y	/ear	IV, Fixed, 95% CI	
TIAN Meiling 2020	5.32	1.4	22	2.18	0.4	22	4.9%	3.14 [2.53, 3.75] 2	2020		
ZHENG Songting 2010	5.1	1.3	20	2.2	0.4	20	5.2%	2.90 [2.30, 3.50] 2	2010		
XIE Danhong 2007	5.1	1.3	30	2.2	0.4	30	7.7%	2.90 [2.41, 3.39] 2	2007		
LV Jianzhong 2003	7.2	0.32	22	6.8	0.2	22	73.6%	0.40 [0.24, 0.56] 2	2003		
WANG Xiaomin 1995	2.86	1.32	36	1.43	0.52	36	8.5%	1.43 [0.97, 1.89] 1	995		
Total (95% CI) 130 1							100.0%	0.95 [0.81, 1.08]		•	
Heterogeneity: Chi ² = 203	3.39, df =	4 (P < (0.00001	l); l ² = 9	8%					-2 -1 0 1 2	
Test for overall effect: Z = 13.69 (P < 0.00001) Favours [Control] Favours [Treatment]											

B

Treatment group			Cont	rol gro	oup		Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	Year	IV, Fixed, 95% CI
NIE Mei 2021	3.37	0.46	46	1.16	0.24	46	76.9%	2.21 [2.06, 2.36]	2021	_
TIAN Meiling 2020	3.62	1.26	22	1.2	0.71	22	4.7%	2.42 [1.82, 3.02]	2020	
ZHENG Songting 2010	3.7	1.1	20	1.2	0.7	20	5.3%	2.50 [1.93, 3.07]	2010	
XIE Danhong 2007	3.7	1.1	30	1.2	0.7	30	7.9%	2.50 [2.03, 2.97]	2007	
LV Jianzhong 2003	2.3	1.26	22	2.8	0.6	22	5.1%	-0.50 [-1.08, 0.08]	2003	
Total (95% CI) 140							100.0%	2.12 [1.99, 2.25]		+
Test for everall offect: 7 -	21 60 /0		.00001)	, 1- = 95	70					-2 -1 0 1 2
Favours [Control] Favours										

С

	Treatment group			Cont	rol gro	oup		Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	Year	IV, Fixed, 95% CI	
NIE Mei 2021	0.13	0.04	46	0.31	0.06	46	96.9%	-0.18 [-0.20, -0.16]	2021		
ZHENG Songting 2010	1.6	0.3	20	2.1	0.3	20	1.2%	-0.50 [-0.69, -0.31]	2010		
XIE Danhong 2007	1.6	0.3	30	2.1	0.3	30	1.8%	-0.50 [-0.65, -0.35]	2007		
LV Jianzhong 2003	0.24	0.96	22	0.37	1.26	15	0.1%	-0.13 [-0.88, 0.62]	2003		
Total (95% CI)			118			111	100.0%	-0.19 [-0.21, -0.17]			
Heterogeneity: Chi ² = 27.60, df = 3 (P < 0.00001); l ² = 89% Test for overall effect: Z = 18.13 (P < 0.00001) Favours [Control] Favours [Treatment]											







Ε

F

Figure6

D

	Treatment g	group	Control	group		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	Year	M-H, Random, 95% Cl
NIE Mei 2021	45	46	35	46	1.7%	14.14 [1.74, 114.83]	2021	· · · · · · · · · · · · · · · · · · ·
TIAN Meiling 2020	19	22	12	22	3.0%	5.28 [1.20, 23.16]	2020	
XUE Feng 2019	46	50	36	50	4.1%	4.47 [1.36, 14.76]	2019	
CHANG Xinyu 2019	41	43	31	43	2.8%	7.94 [1.65, 38.06]	2019	
GAO Xiang 2018	44	45	34	45	1.7%	14.24 [1.75, 115.72]	2018	· · · · · · · · · · · · · · · · · · ·
LI Xiaoli 2017	36	40	24	40	4.0%	6.00 [1.79, 20.15]	2017	
CHI Pengwei 2017	50	54	32	54	4.3%	8.59 [2.71, 27.25]	2017	
MA Chufeng 2016	38	40	31	40	2.7%	5.52 [1.11, 27.43]	2016	
AO Wen 2015	37	40	23	40	3.5%	9.12 [2.40, 34.58]	2015	
LI Xiaohua 2015	54	57	45	57	3.6%	4.80 [1.28, 18.07]	2015	
LUO Jia 2015	22	28	15	22	3.8%	1.71 [0.48, 6.11]	2015	
ZHANG Jianfei 2014	21	25	17	24	3.3%	2.16 [0.54, 8.64]	2014	
XU Jianping 2014	37	42	24	42	4.5%	5.55 [1.82, 16.94]	2014	
CUI Huanhuan 2013	29	45	15	30	5.5%	1.81 [0.71, 4.64]	2013	
JIANG Weihua 2013	40	42	32	42	2.7%	6.25 [1.28, 30.58]	2013	
Liao Xuedong 2012	29	33	20	33	3.8%	4.71 [1.34, 16.57]	2012	
GOU Xiaoyan 2012	12	24	13	24	4.4%	0.85 [0.27, 2.63]	2012	
ZHANG Zhiyu 2010	44	50	28	48	5.0%	5.24 [1.87, 14.64]	2010	
HE Xiaohui 2010	23	23	16	16		Not estimable	2010	
ZHENG Songting 2010	16	20	9	20	3.3%	4.89 [1.20, 19.94]	2010	
WANG Xiusheng2009	53	61	32	45	5.2%	2.69 [1.01, 7.20]	2009	
WEI Xiaobo 2009	37	42	24	42	4.5%	5.55 [1.82, 16.94]	2009	
XIE Danhong 2007	26	30	14	30	3.8%	7.43 [2.08, 26.55]	2007	
ZUO Lingjing 2007	70	105	46	110	8.6%	2.78 [1.60, 4.85]	2007	
WANG Lan 2007	7	13	3	15	2.5%	4.67 [0.88, 24.80]	2007	
WANG Wei 2004	18	24	14	24	4.0%	2.14 [0.63, 7.33]	2004	
LUO Yan 2002	53	60	4	26	3.6%	41.64 [11.07, 156.70]	2002	
Total (95% CI)		1104		1030	100.0%	4.45 [3.31, 5.99]		•
Total events	947		629					
Heterogeneity: Tau ² = 0.1	19; Chi ² = 37.5	58, df = 2	25 (P = 0.0	5); l² = 3	3%			
Test for overall effect: Z =	= 9.84 (P < 0.0	00001)						U.UI U.I I 10 100
								ravours [Control] ravours [rreatment]





